On Your Mark, Get Set, Go!
GlycoMark is pleased to offer our newsletter to physicians, clinicians and laboratory professionals. With the increase in the availability and utilization of GlycoMark, our goal is to share the latest research and information regarding the testing, monitoring and treatment of diabetes.
GlycoMark Takes Lead in Diabetes Awareness Month

11 Laboratories Join in Innovative Outreach Campaign

Nearly 30 million people in the United States suffer from the epidemic of diabetes1. However, nearly 40% of diabetes patients in “good control” have persistently elevated glucose levels (hyperglycemia) and significant glucose variability2. These patients are at high risk of developing serious complications, including cardiovascular events. If left untreated, hyperglycemia can lead to cardiovascular disease, nerve damage, kidney damage and eye disease or blindness3.
 
As part of Diabetes Awareness Month, educators and clinical laboratories began a campaign to educate the public on an advanced diagnostic tool that provides a more complete picture of hyperglycemia. The GlycoMark test measures the 1,5-anhydroglucitol molecule in the blood, providing a clinically proven one- to two-week measure of glycemic excursions, often related to post prandial sugar spikes. This is in contrast to A1C, a test that reflects an average blood glucose levels over a two- to three-month time period. 
A1C Manufacturer Collaborates with GlycoMark for New Diabetes Panel

Diazyme Laboratories unveiled its new diabetes panel featuring GlycoMark at the largest gathering of the clinical chemistry professionals in the country, AACC's Annual Scientific Meeting and Clinical Expo in Philadelphia. The comprehensive panel also includes Glycated Serum Protein/GSP and Enzymatic HbA1c. 
Director of Scientific Affairs
Attends FDA Public Workshop
Jeff Dahlen, Ph.D., GlycoMark's Director of Scientific Affairs attended the FDA's public workshop, Diabetes Outcome Measures Beyond Hemoglobin A1c (HbA1c) on August 20th. The workshop discussed the need to change the current regulatory paradigm in order to address the needs of patients with diabetes and to identify additional outcomes, beyond HbA1c, that are of direct relevance and importance to patients living with the disease.
[1] “2014 National Diabetes Statistics Report.” CDC, http://www.cdc.gov/diabetes/data/statistics/2014StatisticsReport.html
[2] Bonora et al., “Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus.” Diabetologia, May 2006
[3] “Hyperglycemia in diabetes.” http://www.mayoclinic.org/diseases-conditions/hyperglycemia/basics/complications/con-20034795
Copyright © *|CURRENT_YEAR|* *|LIST:COMPANY|*, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

GlycoMark.com